Baricitinib plus remdesivir linked to reduced risk of death, progression to invasive mechanical ventilation.

For each 10-fold increase in Spike IgG titer at delivery, risk for infection reduced 47% for infants, regardless of boost.

Increased risk seen for fatigue and chronic fatigue, with hazard ratios of 1.68 and 4.32 compared with non-COVID-19 controls.

Variation seen in weighted age- and sex-standardized prevalence from 1.9 percent in Virgin Islands to 10.6 percent in West Virginia

A spring booster would be the same shot approved last fall, which targets the XBB.1.5 subvariant.

Accuracy of self- and clinician-performed rapid antigen tests appears to be similar.

Symptoms linked to increased odds of at least moderate interference with functioning, lower odds of full-time employment.

Likelihood of receiving HPV vaccine dose higher for children with private health insurance and for those with disability.

In a large study, there were lower odds of neonatal mortality associated with vaccination.

Increases in outpatient visits persist at lower levels through 12 months